Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.67 USD | +3.73% | +3.27% | -4.73% |
May. 31 | Sector Update: Health Care Stocks Higher Late Afternoon | MT |
May. 31 | Sector Update: Health Care | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 14.95M | Capitalization | 492M |
---|---|---|---|---|---|
Net income 2024 * | -114M | Net income 2025 * | -111M | EV / Sales 2024 * | - |
Net cash position 2024 * | 218M | Net cash position 2025 * | 105M | EV / Sales 2025 * | 25.9 x |
P/E ratio 2024 * |
-3.84
x | P/E ratio 2025 * |
-4.83
x | Employees | 118 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.77% |
Latest transcript on KalVista Pharmaceuticals, Inc.
1 day | +3.73% | ||
1 week | +3.27% | ||
1 month | +2.82% | ||
3 months | -14.51% | ||
6 months | +38.27% | ||
Current year | -4.73% |
Managers | Title | Age | Since |
---|---|---|---|
Ed Feener
FOU | Founder | 64 | 04-03-25 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 16-07-31 |
Paul Audhya
CTO | Chief Tech/Sci/R&D Officer | 51 | 21-05-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Brian Pereira
CHM | Chairman | 65 | 19-01-31 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 16-07-31 |
Albert Cha
BRD | Director/Board Member | 51 | 15-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 2 M€ | -.--% | ||
0.03% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | +9.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 11.67 | +3.73% | 234,800 |
24-05-30 | 11.25 | +0.90% | 151,971 |
24-05-29 | 11.15 | +0.63% | 246,280 |
24-05-28 | 11.08 | -1.95% | 362,737 |
24-05-24 | 11.3 | +0.09% | 242,589 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.73% | 492M | |
-2.29% | 89.87B | |
-3.95% | 37.57B | |
-13.07% | 32.75B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B |
- Stock Market
- Equities
- KALV Stock